Company
Syndesi Therapeutics
- Status
- Acquiredas of 2026-09-23Source (opens in a new tab)
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Syndesi Therapeutics was developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission. Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi was sold to Abbvie in 2022 for $130M up front and additional consideration of up to $870M based on achievement of development and commercial milestones
About the company
- Status notes
- Syndesi was sold to Abbvie in 2022 for $130M up front and additional consideration of up to $870M based on achievement of development and commercial milestones
Exit
- Acquisition
- 2022$130M up front and additional consideration of up to $870M based on achievement of development and commercial milestones
Loading relationship preview